Rockland Immunochemicals Acquires Epi-Plus® Product Line
News Apr 09, 2013
Epi-Plus® antibodies are widely regarded as the most well validated antibodies available for epigenetics research. All Epi-Plus® antibodies are multi-assay validated, including dot blot testing using modified peptide arrays, western blots, and chromatin immunoprecipitation (ChIP).
Current research in Epigenetics, the study of changes in gene expression or cellular phenotype, has shown that epigenetic pharmaceuticals could be a putative replacement or adjuvant therapy for currently accepted treatment methods such as radiation and chemotherapy. The global revenue market for epigenetics has been estimated at $2.6 Billion in 2012 and is expected to reach $8 Billion by 2017, a five-year CAGR of 25%.
"The acquisition of the Epi-Plus® product line expands Rockland’s Life Science Tools portfolio and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars," commented Jim Fendrick, President and CEO of Rockland Immunochemicals. “The fact that the Epi-Plus® brand is co-owned by Novus Biologicals also allows us to expand the Rockland brand globally."
“As 21st Century Biochemicals continues to focus its efforts on providing US manufactured custom peptide and antibody solutions for its customers, we are pleased that the Epi-Plus® product line is a strong strategic fit for the Rockland portfolio,” added Dr. Jordan Fishman, President and CSO of 21st Century Biochemicals.
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.